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Abstract 
Purpose: To evaluate the effect of Eucommia ulmoides extract (EUE) on osteoblast proliferation as well 
as investigate its probable mechanisms of action. 
Methods: EUE was pharmacologically evaluated at three doses. Osteoblast cells were divided as 
follows: Group I: negative control; groups II–IV: received EUE (180, 360 and 540 μg/ml, respectively). 
We performed 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay to 
determine osteoblast viability following treatment. Alkaline phosphatase (ALP), osteocalcin, and 
collagen I levels in osteoblasts were quantified using commercially available kits. Thereafter, mRNA and 
protein expression of ALP, collagen I, osteocalcin, transforming growth factor-β1 (TGF-β1) were 
measured using real-time quantitative PCR (qPCR) and western blot, respectively. 
Results: EUE significantly (p < 0.01) promoted osteoblast proliferation at three treatment doses (180, 
360, and 540 μg/mL). Furthermore, ALP, osteocalcin, collagen I and TGF-β1 expression at both mRNA 
and protein levels increased significantly (all p < 0.05) following EUE treatment. 
Conclusion: The results suggest that EUE may promote osteoblast cell proliferation and that ALP, 
osteocalcin, collagen I and TGF-β1 gene expression may be involved in the mechanism of action. 
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Osteoporosis reduces bone mass by destroying 
bone microstructure, leading to increased bone 
fragility. This systemic bone metabolic disease 
increases the risk of bone fracture [1,2]. 
 
Eucommia ulmoides is a perennial deciduous 
tree that is endemic to China and protected by 
the government. This plant is often used for 
medicinal purposes. Eucommia ulmoides has 
been used in several pharmacological 
applications, such as treating back and knee 
pain, addressing Qi deficiencies (Bu Zhong), and 
strengthening bone [3]. Eucommia ulmoides has 
also been used to treat numbness, certain types 
of liver deficiencies, tinea cruris, and other 
conditions. Modern pharmacological research 
shows that Eucommia ulmoides can remove 
metabolic byproducts from the body, enhance 
cellular metabolism, prevent skeletal muscle 
aging, balance blood pressure and cholesterol, 
reduce body fat, restore vascular elasticity, treat 
diuresis, exert broad-spectrum anti-bacterial 
activity, excite the central nervous system, and 
improve immune response [4,5]. 
Here, the effects of Eucommia ulmoides extract 
on cell viability and ALP, collagen I, osteocalcin, 
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and TGF-β1 mRNA and protein levels in 






We collected Eucommia ulmoides plants from 
XiangYang City, HuBei Province, China in 2015. 
Dr. Chen identified the taxonomy of the plant, 
and we deposited a voucher specimen (no. 
20150611) at the Chinese National Herbarium 
(Chinese Academy of Sciences). Eucommia 
ulmoides extract was prepared in our laboratory 
as follows. Dried Eucommia ulmoides bark was 
boiled with eight volumes of water for 2 h. The 
sample was centrifuged at 14,000 g for 15 min. 
We collected the supernatant, evaporated it 
under vacuum, and lyophilized it (yield 84.6 g). 
 
The Animal Ethical Care and Use Committee of 
Dalian Medical University, China approved all 
experiments (Ethical permit no. 04/S0356/711). 
Experiments complied with institutional 
guidelines and the National Research Council 
Guide for the Care and Use of Laboratory 
Animals [6]. 
 
MTT assay  
 
Extract was dissolved in DMSO (512 μg/mL). 
Extract was serially diluted two-fold twelve times 
(concentration range, 0.25 – 512 μg/mL). 
Osteoblasts were treated with extract for 72 h. 
The microtiter plates were sealed with EVA 
Capmats™ and allowed to incubate in humidified 
conditions at 37 °C and 5 % CO2. Unsealed 
plates of treated cells were also set up as a 
control. Following treatment, 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide 
(MTT) was prepared in EMEM medium to a final 
concentration of 1 mg/mL and pipetted in wells. 
Then, we incubated plates for another 2 h at the 
above culture conditions. DMSO (0.15 mL) was 
added to each well, and plates were rocked until 
the crystals in the culture medium dissolved 
completely. Using a microplate reader, we 
measure the absorbance (OD) at 570 nm. 
 
Quantitation of ALP, collagen I, and 
osteocalcin levels in osteoblasts 
 
Osteoblasts were treated for 72 h as described 
above. We measured ALP, osteocalcin, and 
collagen I levels using commercially available 
kits, according to the manufacturers’ protocols. 
PCR analysis 
 
Osteoblasts were treated for 72 h as described 
above. Total RNA was extracted according to the 
manufacturer’s instructions using the QIAamp 
DNA stool Kit (Qiagen, Hilden, Germany) and 
stored at -80 °C. cDNA was synthesized using a 
reverse transcription kit. RNA samples were 
heated to 42 °C for 30 min then to 95 °C for 3 
min and plated in 96-well reaction plates in 
triplicate. Each reaction included 10 μL 2× SYBR 
Premix Ex Taq, 1 μL forward primer, 1 μL 
reverse primer (Table 1), 3 μL cDNA, and 5 μL 
nuclease-free water. We performed RT-qPCR 
using a Light Cycler 480 II (Roche Diagnostics) 
and measured cycle threshold (Ct) values to 
calculate the relative amounts of amplified PCR 
products. β-actin was used as a reference. 
 
Table 1: Primers and their sequences 
 



































Osteoblast were treated with extract for 48 h, 
washed with cold PBS three times, and lysed in 
RIPA buffer for 30 min on ice. Samples were 
centrifuged (12000 rpm, 4 °C, 20 min). The total 
protein concentration of the clarified lysate was 
determined using the BCA protein assay (Pulilai, 
China). The samples were resuspended in 
protein-loading buffer and loaded onto a 10 % 
SDS-PAGE gel. Approximately 80 μg of total 
protein was loaded per lane. We performed 
electrophoresis at 100 mV and transferred 
proteins to a polyvinylidene fluoride membrane at 
300 mA. The membrane was blocked with 5 % 
skim milk, probed with primary antibodies 
overnight, and washed. We incubated the 
membrane with a 1:2000 dilution of anti-rabbit or 
anti-mouse secondary antibody conjugated to 
horseradish peroxidase (HRP) (Pulilai, China) for 
2 h. The bands were evaluated using an 
enhanced chemiluminescence detection system. 
Densitometric analysis was performed using a 





Experimental data are expressed as mean ±  
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standard error of the mean. SPSS version 20 
was used for analyses. Among-group differences 
were analyzed using Analysis of Variance 
(ANOVA) and Dunnett’s t-test. A p value < 0.05 




Compared with the normal control group, 
Eucommia ulmoides extract treatment 
significantly increased osteoblast growth in a 
dose-dependent manner (all p < .05). 
Additionally, osteoblast growth rate increased 
significantly with prolonged Eucommia ulmoides 
extract treatment (Table 2). 
 
ALP, osteocalcin and collagen I levels in 
osteoblasts increased significantly (all p < .05) 
following treatment with Eucommia ulmoides 
extract (Table 3). Further, a dose-dependent 
effect was observed. The effect was especially 
obvious at high extract concentrations. 
 
Similarly, ALP, collagen I, osteocalcin, and TGF-
β1 mRNA levels in osteoblast increased 
significantly (all p < .05) and a dose-dependent 
effect was observed following treatment with 
Eucommia ulmoides extract (Table 4). Again, the 
effect was more pronounced at higher extract 
concentrations. 
 
Protein expression levels confirm the above 
results. As before ALP, osteocalcin, TGF-β1, and 
collagen I protein levels increased significantly 
(all p < 0.05) following Eucommia ulmoides 
extract treatment, and the same dose-dependent 
effect was observed (Figure 1).  
 
 
Figure 1: Effect of Eucommia ulmoides extract 
treatment on ALP, osteocalcin, collagen I, and TGF-β1 




Bone tissue can renew itself by mineralizing an 
organic matrix. The process of bone remodeling 
is a delicate balancing act between osteoblast 
bone formation and osteoclast bone resorption 
[7,8]. 
 
When this balance is disrupted, the result is 
osteopathic diseases, including Paget’s disease 
and osteoporosis [9]. Older women commonly  
 
Table 2: Effect of Eucommia ulmoides extract (EUE) treatment on osteoblast growth 
 
Group  MTT 
24 h 48 h 72 h 
NC 0.1853±0.0131 0.3275±0.0242 0.3371±0.0264 
EUE (180 μg/mL) 0.1951±0.0138 0.3281±0.0283 0.3516±0.0251 * 
EUE (360 μg/mL) 0.2028±0.0127 0.3482±0.0241* 0.3718±0.0283** 
EUE (540μg/mL) 0.2112±0.0166 0.3629±0.0242** 0.4172±0.0306** 
*P < .05, **p < .01 compared with the normal control (NC) group 
 
Table 3: Effect of Eucommia ulmoides extract (EUE) treatment on ALP, osteocalcin, and collagen I levels in 
osteoblasts 
 
Group  ALP (μKat/g) Osteocalcin (ng/106) Collagen I (ng/mL) 
NC 12.52 ± 1.08 2.97 ± 0.18 10.37 ±0.93 
EUE (180 μg/mL) 14.27 ± 1.14 3.31 ±0.24 * 12.03 ± 1.05 
EUE (360 μg/mL) 16.38 ± 1.09* 3.49 ±0.22** 16.29 ± 1.17** 
EUE (540μg/mL) 17.34 ± 1.13* 4.15 ± 0.31** 22.71 ± 1.82 ** 
* p < .05, **p < .01 compared with the normal control (NC) group 
 
Table 4: Effect of Eucommia ulmoides extract (EUE) treatment on the relative mRNA expression level of ALP, 
collagen I, osteocalcin, and TGF-β1 in osteoblasts  
 
Group  ALP mRNA  Collagen I mRNA  Osteocalcin mRNA  TGF-β1 mRNA  
NC 1.01 ± 0.03 1.03 ± 0.01 1.04 ± 0.02 1.02 ± 0.01 
EUE (180 μg/mL) 0.99 ± 0.02 1.08 ± 0.03 1.11 ± 0.04 1.13 ± 0.02* 
EUE (360 μg/mL) 1.18 ± 0.05 1.18 ± 0.04* 1.26 ± 0.04** 1.29 ± 0.04** 
EUE (540 μg/mL) 1.25 ± 0.03* 1.21 ± 0.05** 1.34 ± 0.03 ** 1.42 ± 0.06** 
*P < .05; **p < .01 compared with the normal control (NC) group. Values normalized to β-actin 
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develop osteoporosis because their estrogen 
levels decrease following menopause 
 
Traditional Chinese medicine considers 
Eucommia ulmoides Oliv. to be valuable because 
of its anti-bacterial, anti-inflammation, immune-
boosting, and anti-osteoporosis effects [10]. One 
study showed that consumption of Eucommia 
ulmoides bark extract inhibits estrogen-
deficiency-induced bone loss in ovariectomized 
rats. Specifically, the extract slowed bone 
resorption and increased osteoblast activity [11].  
 
Alkaline phosphatase (ALP) is an enzyme 
involved in osteoblast and osteoblast 
differentiation. It plays a key role in calcification 
in vitro. Alkaline phosphatase can hydrolyze 
organic phosphatase, which increases the local 
concentration of PO43-. The combination of PO43- 
and Ca2+, initiates calcification. Osteocalcin, a 
major non-collagenous protein in the bone 
matrix, is the only bone extracellular matrix 
protein produced exclusively by osteoblasts. 
Osteocalcin contributes to bone formation, 
making it a specific marker of osteoblast function. 
TGF-β is commonly expressed in numerous 
tissues, and the TGF-β1 subtype is highly 
expressed in bone tissue. Type 1 collagen is the 
primary component of the extracellular matrix 
because it serves as a framework for the 
hydroxyapatite deposition reaction.  
 
Our results showed that Eucommia ulmoides 
extract promoted osteoblast proliferation and 
increased ALP, collagen I, osteocalcin, and TGF-
β1 levels of both mRNA and protein in 
osteoblasts.  
 
Limitation of the study 
 
There is one limitation to this study. The bone-
promotion effects of Eucommia ulmoides extract 
in ovariectomized animals, such as bone loss 
inhibition, were not examined. We will address 




This study demonstrates that Eucommia 
ulmoides extract has beneficial effects on 
osteoblast growth. Specifically, Eucommia 
ulmoides extract treatment significantly promotes 
osteoblast growth and increases ALP, collagen I, 
and osteocalcin secretion. These results indicate 
that Eucommia ulmoides extract may affect 
osteoblast cell differentiation and stimulate the 
growth of osteoblast cells by increasing ALP, 
osteocalcin, collagen I, and TGF-β1 levels. 
Eucommia ulmoides extract could possibly be 
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